Literature DB >> 8327704

Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage.

M Remy-Jardin1, J Remy, B Wallaert, D Bataille, P Y Hatron.   

Abstract

Computed tomographic (CT) findings obtained in 53 patients with progressive systemic sclerosis were correlated with functional parameters and bronchoalveolar lavage (BAL) results, and lung changes over time were assessed in 17 patients. CT findings were normal in 21 patients (group 1) with otherwise normal lung function, except for subclinical alveolitis in seven patients. CT depicted pleural and parenchymal abnormalities in 32 patients, grouped according to the absence (group 2) or presence (group 3) of honeycombing. In group 2 (n = 13), mean values of functional parameters were normal, and BAL showed a significant increase in neutrophils compared to group 1 (P < .05). Among patients in group 3 (n = 19) with limited extent of honeycombing (n = 12), the mean diffusing capacity value was lower in patients with a moderate ground-glass profusion score (n = 4) than in those with a mild score (n = 8) (68% +/- 4 [standard error of the mean] vs 80% +/- 3). CT is the method of choice for evaluating parenchymal destruction, and profusion and extent of ground-glass opacities can help in predicting the severity of lung damage in areas devoid of destructive changes.

Entities:  

Mesh:

Year:  1993        PMID: 8327704     DOI: 10.1148/radiology.188.2.8327704

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

Review 1.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  [Pulmonary manifestations in rheumatic systemic diseases].

Authors:  T Schlossbauer; C Becker-Gaab; R Eibel
Journal:  Radiologe       Date:  2005-07       Impact factor: 0.635

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

5.  The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis.

Authors:  Thi Dan Linh Nguyen-Kim; Britta Maurer; Yossra A Suliman; Fabian Morsbach; Oliver Distler; Thomas Frauenfelder
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Treating CTDs related fibrotic ILDs by immunosuppressants: "facts and faults".

Authors:  Spyros A Papiris; Konstantinos Kagouridis; Georgia Papadaki; Likurgos Kolilekas; Effrosyni D Manali
Journal:  Lung       Date:  2013-11-12       Impact factor: 2.584

Review 7.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

Review 8.  Imaging lung disease in systemic sclerosis.

Authors:  Diane Strollo; Jonathan Goldin
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

9.  Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography.

Authors:  Maurizio Zompatori; Maria Barbara Leone; Marica Giannotta; Nazzareno Galiè; Massimiliano Palazzini; Maria Letizia Bacchi Reggiani; Lea Bono; Gian Stefano Pollini
Journal:  Radiol Med       Date:  2013-05-27       Impact factor: 3.469

10.  Feasibility of automated quantification of regional disease patterns depicted on high-resolution computed tomography in patients with various diffuse lung diseases.

Authors:  Sang Ok Park; Joon Beom Seo; Namkug Kim; Seong Hoon Park; Young Kyung Lee; Bum-Woo Park; Yu Sub Sung; Youngjoo Lee; Jeongjin Lee; Suk-Ho Kang
Journal:  Korean J Radiol       Date:  2009-08-25       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.